 Angiotensin II
"Angiotensin II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
| Descriptor ID |
D000804
|
| MeSH Number(s) |
D06.472.699.094.078 D12.644.400.070.078 D12.644.456.073.041 D12.644.548.058.078 D12.776.631.650.070.078 D23.469.050.050.050
|
| Concept/Terms |
Angiotensin II- Angiotensin II
- ANG-(1-8)Octapeptide
- Angiotensin-(1-8) Octapeptide
Angiotensin II, Ile(5)-- Angiotensin II, Ile(5)-
- Angiotensin II, Isoleucine(5)-
- 5-L-Isoleucine Angiotensin II
- 5 L Isoleucine Angiotensin II
- Angiotensin II, 5-L-Isoleucine
- Isoleucine(5)-Angiotensin
- Isoleucyl(5)-Angiotensin II
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin II".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin II".
This graph shows the total number of publications written about "Angiotensin II" by people in this website by year, and whether "Angiotensin II" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 2 | 3 | | 1996 | 0 | 2 | 2 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2000 | 3 | 2 | 5 | | 2001 | 1 | 0 | 1 | | 2002 | 0 | 3 | 3 | | 2003 | 4 | 2 | 6 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 2 | 3 | | 2006 | 3 | 1 | 4 | | 2007 | 4 | 1 | 5 | | 2008 | 2 | 3 | 5 | | 2010 | 0 | 1 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 0 | 2 | 2 | | 2013 | 2 | 3 | 5 | | 2014 | 3 | 0 | 3 | | 2015 | 3 | 2 | 5 | | 2016 | 0 | 2 | 2 | | 2018 | 0 | 1 | 1 | | 2019 | 1 | 1 | 2 | | 2020 | 2 | 2 | 4 | | 2021 | 0 | 2 | 2 | | 2022 | 1 | 1 | 2 | | 2023 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin II" by people in Profiles.
-
Jagadeesh T, Choudhury S, Gari M, Singh V, Shukla A, Garg SK. Sepsis modulates aortic AT1 and P2Y6 receptors to produce vascular hyporeactivity in mice. J Recept Signal Transduct Res. 2023 Dec; 43(2):37-49.
-
Self WH, Shotwell MS, Gibbs KW, de Wit M, Files DC, Harkins M, Hudock KM, Merck LH, Moskowitz A, Apodaca KD, Barksdale A, Safdar B, Javaheri A, Sturek JM, Schrager H, Iovine N, Tiffany B, Douglas IS, Levitt J, Busse LW, Ginde AA, Brown SM, Hager DN, Boyle K, Duggal A, Khan A, Lanspa M, Chen P, Puskarich M, Vonderhaar D, Venkateshaiah L, Gentile N, Rosenberg Y, Troendle J, Bistran-Hall AJ, DeClercq J, Lavieri R, Joly MM, Orr M, Pulley J, Rice TW, Schildcrout JS, Semler MW, Wang L, Bernard GR, Collins SP. Renin-Angiotensin System Modulation With Synthetic Angiotensin (1-7) and Angiotensin II Type 1 Receptor-Biased Ligand in Adults With COVID-19: Two Randomized Clinical Trials. JAMA. 2023 04 11; 329(14):1170-1182.
-
Gutierrez GC, Dayton C, Attridge RL, Smedley L, Saikumar H, Everett C, Rodriguez A, Varney S. Angiotensin II Use in Treatment of Refractory Shock Due to Benazepril and Amlodipine Toxic Ingestion. J Pharm Pract. 2024 Apr; 37(2):513-516.
-
Venkatasubramanian R, Mahoney SA, Clayton ZS. Could angiotensin-II induced T-cell senescence exacerbate age-related vascular dysfunction? J Physiol. 2022 04; 600(8):1821-1823.
-
Muehleman DL, Crocini C, Swearingen AR, Ozeroff CD, Leinwand LA. Regression from pathological hypertrophy in mice is sexually dimorphic and stimulus specific. Am J Physiol Heart Circ Physiol. 2022 05 01; 322(5):H785-H797.
-
Wellman K, Fu R, Baldwin A, Rege J, Murphy E, Rainey WE, Mukherjee N. Transcriptomic Response Dynamics of Human Primary and Immortalized Adrenocortical Cells to Steroidogenic Stimuli. Cells. 2021 09 09; 10(9).
-
Ferguson BS, Wennersten SA, Demos-Davies KM, Rubino M, Robinson EL, Cavasin MA, Stratton MS, Kidger AM, Hu T, Keyse SM, McKnight RA, Lane RH, Nozik ES, Weiser-Evans MCM, McKinsey TA. DUSP5-mediated inhibition of smooth muscle cell proliferation suppresses pulmonary hypertension and right ventricular hypertrophy. Am J Physiol Heart Circ Physiol. 2021 08 01; 321(2):H382-H389.
-
Piani F, Reinicke T, Lytvyn Y, Melena I, Lovblom LE, Lai V, Tse J, Cham L, Orszag A, Perkins BA, Cherney DZI, Bjornstad P. Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease. J Diabetes Complications. 2021 03; 35(3):107807.
-
Weinberger T, Esfandyari D, Messerer D, Percin G, Schleifer C, Thaler R, Liu L, Stremmel C, Schneider V, Vagnozzi RJ, Schwanenkamp J, Fischer M, Busch K, Klapproth K, Ishikawa-Ankerhold H, Kl?sges L, Titova A, Molkentin JD, Kobayashi Y, Engelhardt S, Massberg S, Waskow C, Perdiguero EG, Schulz C. Ontogeny of arterial macrophages defines their functions in homeostasis and inflammation. Nat Commun. 2020 09 11; 11(1):4549.
-
Chow JH, Wallis M, Lankford AS, Chancer Z, Barth RN, Scalea JR, LaMattina JC, Mazzeffi MA, McCurdy MT. Treatment of Renin-Angiotensin-Aldosterone System Dysfunction With Angiotensin II in High-Renin Septic Shock. Semin Cardiothorac Vasc Anesth. 2021 Mar; 25(1):67-73.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|